subscribeSubscribe
Debiopharm, Aspen Partner To Launch Prostate Cancer Drug Trelstar In S. Africa

Debiopharm, Aspen Partner To Launch Prostate Cancer Drug Trelstar In S. Africa
PRNEWSWIRE
01 Feb 2022
Share Share
Ipsen poaches Novartis vet Mari Scheiffele

Ipsen poaches Novartis vet Mari Scheiffele
Eric Sagonowsky FIERCEPHARMA
11 Oct 2021
Share Share
Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin)

Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin)
PRNEWSWIRE
25 Aug 2020
Share Share
Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin)

Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin)
PRNEWSWIRE
25 Aug 2020
Share Share
Myovant`s oral prostate cancer drug matches incumbent in phase 3

Myovant`s oral prostate cancer drug matches incumbent in phase 3
N. P Taylor FIERCE BIOTECH
20 Nov 2019
Share Share
Myovant`s oral prostate cancer drug matches incumbent in phase 3

Myovant`s oral prostate cancer drug matches incumbent in phase 3
N. P Taylor FIERCE BIOTECH
20 Oct 2019
Share Share
Myovant`s oral prostate cancer drug matches incumbent in phase 3

Myovant`s oral prostate cancer drug matches incumbent in phase 3
N. P Taylor FIERCE BIOTECH
20 Oct 2019
Share Share
Arbor & Debiopharm International Announce Commercial Availability of Triptodur

Arbor & Debiopharm International Announce Commercial Availability of Triptodur
PR NEWSWIRE
03 Oct 2017
Share Share
Arbor & Debiopharm Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation

Arbor & Debiopharm Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation
PR NEWSWIRE
01 Jul 2017
Share Share
Debiopharm’s triptorelin 6-month formulation receives EU approval

Debiopharm’s triptorelin 6-month formulation receives EU approval
Niamh Marriott EU PHARMACEUTICAL
20 Mar 2017
Share Share